Products
Preparation registered in Ukraine
Danilova A.
Optix in treatment of diabetic retinopathy in diabetic patients
In this article the etiopathogenesis, clinical manifestations, classification, diagnosis and principles of treatment of diabetic retinopathy (DR) are discussed. There is focus on the use of the drug Optix (“Kyiv Vitamin Factory”) in treatment of this pathology. Use of the drug Optix is aimed for inhibition of pathogenic mechanisms that lead to the development of diabetic retinopathy by protecting the vascular wall of the eye from free radicals. Optix can be recommended to be included in complex therapy of patients with diabetes mellitus (DM) from the first years of disease. Patients with diabetes with DR require prolonged treatment (up to 3 months) with a repetition rate in six months. Patients who received treatment by laser coagulation require treatment with Optix within 3 months before and after treatment.
Key words: diabetes mellitus, diabetic retinopathy, Optix.